PrenaTest®

Non-invasive examination for the determination of fetal trisomies 21, 18 and 13 such as Klinefelter syndrome, Turner-, Triple X-,  XYY syndrome and a 22q11.2 microdeletion

Based on molecular genetic methods such as qPCR and next generation sequencing technologies, the non-invasive molecular genetic PrenaTest® determines fetal trisomies 21, 18 and 13, gonosomal aneuploidies (Turner, triple X, Klinefelter, and XYY syndromes) and the 22q11.2 microdeletion, associated with DiGeorge syndrome and velo-cardio-facial syndrome (Shprintzen syndrome), in the maternal blood with a high level of reliability. This supplements conventional prenatal diagnostic methods and does not involve any risk of procedure-related miscarriage unlike in the case of invasive methods, such as amniocentesis. The PrenaTest® is the method of choice from the ninth week of pregnancy onward (9+0) for expectant mothers at increased risk for any of the fetal chromosomal disorders listed above.

Print Friendly
top